Abstract | UNLABELLED: LEVEL OF EVIDENCE: Therapeutic study, level II (lesser quality randomized controlled trial [eg, < 80% followup, no blinding, or improper randomization]). See the Guidelines for Authors for a complete description of the levels of evidence.
|
Authors | Jean-Yves Reginster, Jean-Pierre Devogelaer |
Journal | Clinical orthopaedics and related research
(Clin Orthop Relat Res)
Vol. 443
Pg. 48-54
(Feb 2006)
ISSN: 0009-921X [Print] United States |
PMID | 16462425
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Selective Estrogen Receptor Modulators
- Raloxifene Hydrochloride
|
Topics |
- Animals
- Bone Density
(drug effects)
- Female
- Fractures, Bone
(etiology, prevention & control)
- Humans
- Osteoporosis, Postmenopausal
(complications, drug therapy)
- Raloxifene Hydrochloride
(therapeutic use)
- Selective Estrogen Receptor Modulators
(therapeutic use)
- Treatment Outcome
|